Regulated information

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

Universal registration document 2023 XBRL version

Universal Registration Document including the Annual Financial Report

Universal registration document 2023

Universal Registration Document including the Annual Financial Report

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

Information relative au code de gouvernance

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les administrateurs ont adopté le code de gouvernance Middlenext. Depuis 2008, Vétoquinol se référait au code AFEP-MEDEF.

Information relative au Code de Gouvernance (french)

Lors de la réunion du Conseil d’administration du 16 décembre 2014, les
administrateurs ont adopté le code de gouvernance Middlenext. Depuis
2008, Vétoquinol se référait au code AFEP-MEDEF.

Q3 2014 sales up 11.0%

The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates).

Solid growth in Q2 2014: 8.8% first half net income up 4.2%

At its July 30, 2014 meeting, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first six months of 2014.